These pages are dedicated to the ILAE Annual Congress 2026 in Athens, created specifically for the Nordic epilepsy community. Our goal is to provide Nordic healthcare professionals with relevant news, key highlights, and insights from this important event in epilepsy research and care.
At the ILAE Congress, experts discussed a range of topics currently shaping epilepsy care and research. These brief summaries of selected themes offer a quick understanding of what was discussed and the key takeaways from each topic.
Does the current definition fully capture disease complexity?
Scientific debate focused on whether drug-resistant epilepsy should be viewed as a dynamic biological process rather than a binary outcome following treatment failure. Discussions considered the role of biomarkers, disease mechanisms, quality of life measures, and individualized treatment goals in future definitions.
Is epilepsy better understood as a disorder of brain networks rather than isolated seizure foci?
Advances in neuroimaging and electrophysiology continue to improve understanding of the large-scale brain networks involved in epilepsy. Experts discussed how network-based models may influence future approaches to diagnosis, surgical evaluation, neuromodulation, and treatment planning.
Can targeting disease mechanisms alter the course of epilepsy?
Growing evidence links neuroinflammatory processes to seizure generation, disease progression, and cognitive outcomes. EEC 2026 sessions reviewed advances in understanding epileptogenesis and the potential role of inflammation-focused therapeutic strategies in modifying disease activity.
Are biomarkers ready to guide clinical decision-making?
Emerging research highlighted the potential of molecular, imaging, electrophysiological, and digital biomarkers to improve diagnosis, stratify patients, predict outcomes, and support treatment monitoring. While many approaches remain under investigation, the field is rapidly moving toward clinically actionable biomarkers.
Should genetic testing be considered sooner and for more patients?
Presentations at EEC 2026 explored the expanding role of genetic testing across epilepsy syndromes. Evidence presented suggests that earlier identification of genetic aetiologies may improve diagnostic accuracy, inform treatment selection, support prognostic discussions, and facilitate access to precision medicine approaches.
International epilepsy experts came together at the Angelini satellite symposium during the EEC 2026 to discuss current challenges and opportunities in epilepsy care. Explore the short video recordings below for highlights and key takeaways from the faculty. Each presentation is accompanied by selected speaker's slides shown in the symposium.
We are pleased to share talks from the Angelini Pharma Satellite Symposium at the 16th European Epilepsy Congress (EEC).At the heart of Angelini Pharma’s satellite symposium at EEC 2026 was a key question for modern epilepsy care: how can epilepsy care move beyond seizure reduction towards outcomes that are more ambitious and meaningful for patients?The international experts summarize their talks in these short videos – Click to hear their perspectives and insights drawn from clinical practice. Each video contains also selection of symposium slides.We will continue to add recordings, expert perspectives, and other congress materials to this page as new content becomes available, helping you stay up to date with the latest insights from the meeting.
PAUL BOON
This presentation explores the evolving treatment goals in epilepsy care, highlighting the importance of looking beyond seizure control alone. The session discusses how brain health, cognitive function, well-being, and quality of life can be integrated into a more holistic approach to patient management.
Paul Boon is Professor of Neurology at Ghent University and Lead Epileptologist at the Centre for Neurophysiological Monitoring, Ghent University Hospital, Belgium. He is a pioneer of epilepsy surgery and neuromodulation in Europe, past president of EAN and author of more than 800 scientific publications.
MAT-DK-0103-P 16.11.2026